Swiss National Bank
ICVX

Swiss National Bank’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Swiss National Bank’s Portfolio ICVX Stock Details ICVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,700
Closed -$195K – 2809
2022
Q1 		$195K Buy
27,700
+1,600
+6% +$25.2K ﹤0.01% 2677
2021
Q4 		$597K Buy
+26,100
New +$674K ﹤0.01% 2633

Other funds holding ICVX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Swiss National Bank's ICVX Position: Q2 2022 in Review

Swiss National Bank sold out of Icosavax, Inc. Common Stock (ICVX) in Q2 2022, closing a stake of 27,700 shares — an estimated $195K sold.

Swiss National Bank first reported a position in ICVX in Q4 2021 and held it in 2 quarters. The position peaked at $597K in Q4 2021. 57 funds tracked by Wall St. Rank hold ICVX as of Q2 2022.

  • Swiss National Bank reported no remaining Icosavax, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 27,700 Icosavax, Inc. Common Stock shares in Q2 2022, an estimated $195K.
  • Swiss National Bank first reported a position in Icosavax, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Swiss National Bank's Icosavax, Inc. Common Stock position peaked at $597K in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.